The emerging role of oncolytic virus therapy against cancer

Luke Russell, Kah Whye Peng

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.

Original languageEnglish (US)
Article number16
JournalChinese clinical oncology
Issue number2
StatePublished - Apr 1 2018


  • Antitumor immunity
  • Cancer
  • Oncolytic
  • Virus

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'The emerging role of oncolytic virus therapy against cancer'. Together they form a unique fingerprint.

Cite this